Feb 16, 2023 9:25 am EST Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Jan 25, 2023 8:00 am EST Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Jan 19, 2023 4:05 pm EST Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
Jan 12, 2023 9:26 am EST Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Nov 10, 2022 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 03, 2022 4:01 pm EDT Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Oct 06, 2022 9:00 am EDT Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
Aug 10, 2022 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 03, 2022 8:00 am EDT Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10